PMID- 30753687
OWN - NLM
STAT- MEDLINE
DCOM- 20191202
LR  - 20191202
IS  - 1460-2393 (Electronic)
IS  - 1460-2393 (Linking)
VI  - 112
IP  - 6
DP  - 2019 Jun 1
TI  - Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of 
      cholangiocarcinoma: a meta-analysis.
PG  - 421-427
LID - 10.1093/qjmed/hcz039 [doi]
AB  - BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) can suppress the 
      proliferation of cholangiocarcinoma (CCA) cells in vitro through inhibition of 
      cyclooxygenase-2. However, the effects of aspirin and NSAIDs on the risk of CCA 
      remain unclear. We performed this meta-analysis to assess the risk of biliary 
      tract cancers in patients who take aspirin and/or NSAIDs. METHODS: A systematic 
      review was conducted utilizing MEDLINE, EMBASE, Cochrane databases from inception 
      through October 2017 to identify studies that assessed the association of aspirin 
      and/or NSAIDs use with risk of biliary tract cancers including CCA, gallbladder 
      cancer and ampulla of Vater cancer. Effect estimates from the studies were 
      extracted and combined using the random-effect, generic inverse variance method 
      of DerSimonian and Laird. RESULTS: Five observational studies with a total of 9 
      200 653 patients were enrolled. The pooled OR of CCA in patients with aspirin use 
      was 0.56 (95% CI, 0.32-0.96). Egger's regression asymmetry test was performed and 
      showed no publication bias for the association between aspirin use and CCA with P 
      = 0.42. There was no significant association between NSAIDs use and CCA, with a 
      pooled OR of 0.79 (95% CI, 0.28-2.21). One study showed a significant association 
      between aspirin use and reduced risk of gallbladder cancer with OR of 0.37 
      (0.17-0.80). However, there was no significant association between aspirin and 
      ampulla of Vater cancer with OR of 0.22 (0.03-1.65). CONCLUSIONS: Our study 
      demonstrates a significant association between aspirin use and a 0.56-fold 
      decreased risk of CCA. However, there is no association between the use of NSAIDs 
      and CCA.
CI  - (c) The Author(s) 2019. Published by Oxford University Press on behalf of the 
      Association of Physicians. All rights reserved. For permissions, please email: 
      journals.permissions@oup.com.
FAU - Lapumnuaypol, K
AU  - Lapumnuaypol K
AD  - Department of Internal Medicine, Albert Einstein Medical Center, PA, USA.
FAU - Tiu, A
AU  - Tiu A
AD  - Department of Internal Medicine, Albert Einstein Medical Center, PA, USA.
FAU - Thongprayoon, C
AU  - Thongprayoon C
AD  - Department of Nephrology, Mayo Clinic, Nephrology and Hypertension, Rochester, 
      MN, USA.
FAU - Wijarnpreecha, K
AU  - Wijarnpreecha K
AD  - Department of Gastroenterology, Mayo Clinic Hospital Jacksonville, 
      Gastroenterology, Jacksonville, FL, USA.
FAU - Ungprasert, P
AU  - Ungprasert P
AD  - Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
FAU - Mao, M A
AU  - Mao MA
AD  - Department of Nephrology, Mayo Clinic, Nephrology and Hypertension, Rochester, 
      MN, USA.
FAU - Cheungpasitporn, W
AU  - Cheungpasitporn W
AD  - Division of Nephrology, Department of Medicine, University of Mississippi Medical 
      Center, MS, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - England
TA  - QJM
JT  - QJM : monthly journal of the Association of Physicians
JID - 9438285
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - QJM. 2019 Aug 1;112(8):643. PMID: 30907952
CIN - QJM. 2019 Sep 1;112(9):719-720. PMID: 31070755
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Bile Duct Neoplasms/epidemiology/*prevention & control
MH  - Cholangiocarcinoma/epidemiology/*prevention & control
MH  - Humans
MH  - Risk Factors
EDAT- 2019/02/13 06:00
MHDA- 2019/12/04 06:00
CRDT- 2019/02/13 06:00
PHST- 2018/11/23 00:00 [received]
PHST- 2018/12/26 00:00 [revised]
PHST- 2019/02/13 06:00 [pubmed]
PHST- 2019/12/04 06:00 [medline]
PHST- 2019/02/13 06:00 [entrez]
AID - 5308610 [pii]
AID - 10.1093/qjmed/hcz039 [doi]
PST - ppublish
SO  - QJM. 2019 Jun 1;112(6):421-427. doi: 10.1093/qjmed/hcz039.